Compare Stocks: ALDX, IKT, VNDA, and AMRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.30 -4.1%	$1.52	$1.07 ▼ $5.93	$78.13M	1.2	1.75 million shs	163,664 shs
AMRN Amarin	$13.46 -1.9%	$13.98	$12.96 ▼ $20.90	$284.23M	0.76	75,885 shs	10,659 shs
IKT Inhibikase Therapeutics	$2.10 -2.6%	$2.35	$1.33 ▼ $2.61	$293.72M	0.95	1.13 million shs	160,613 shs
VNDA Vanda Pharmaceuticals	$4.99 -1.1%	$5.25	$4.27 ▼ $9.94	$301.39M	0.64	1.53 million shs	194,118 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-3.23%	-1.46%	-11.18%	-25.00%	-73.58%
AMRN Amarin	-0.22%	-0.87%	-0.87%	-16.09%	-10.74%
IKT Inhibikase Therapeutics	-6.93%	-6.93%	-14.00%	+14.97%	+32.72%
VNDA Vanda Pharmaceuticals	-3.26%	+0.80%	-5.44%	-13.85%	+5.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.30 -4.1%	$1.52	$1.07 ▼ $5.93	$78.13M	1.2	1.75 million shs	163,664 shs
AMRN Amarin	$13.46 -1.9%	$13.98	$12.96 ▼ $20.90	$284.23M	0.76	75,885 shs	10,659 shs
IKT Inhibikase Therapeutics	$2.10 -2.6%	$2.35	$1.33 ▼ $2.61	$293.72M	0.95	1.13 million shs	160,613 shs
VNDA Vanda Pharmaceuticals	$4.99 -1.1%	$5.25	$4.27 ▼ $9.94	$301.39M	0.64	1.53 million shs	194,118 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	-3.23%	-1.46%	-11.18%	-25.00%	-73.58%
AMRN Amarin	-0.22%	-0.87%	-0.87%	-16.09%	-10.74%
IKT Inhibikase Therapeutics	-6.93%	-6.93%	-14.00%	+14.97%	+32.72%
VNDA Vanda Pharmaceuticals	-3.26%	+0.80%	-5.44%	-13.85%	+5.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	307.41% Upside
AMRN Amarin	1.33	Sell	$13.00	-5.25% Downside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	151.16% Upside
VNDA Vanda Pharmaceuticals	2.56	Moderate Buy	$13.08	159.59% Upside

Current Analyst Ratings Breakdown

Latest ALDX, IKT, VNDA, and AMRN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	VNDA Vanda Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
9/14/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	AMRN Amarin	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Underweight	$13.00
8/17/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/17/2026	AMRN Amarin	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/10/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$21.00 ➝ $20.00
8/10/2026	VNDA Vanda Pharmaceuticals	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$17.00 ➝ $12.00
7/31/2026	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/17/2026	AMRN Amarin	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IKT Inhibikase Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
AMRN Amarin	$186.23M	1.56	$0.36 per share	38.09	$22.07 per share	0.62
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$2.30 per share	N/A
VNDA Vanda Pharmaceuticals	$216.10M	1.41	N/A	N/A	$5.54 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.39	N/A	N/A	N/A	N/A	-53.14%	-34.94%	11/4/2026 (Estimated)
AMRN Amarin	-$38.80M	-$0.99	N/A	N/A	N/A	-14.56%	-0.20%	-0.14%	11/4/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	11/4/2026 (Estimated)

Latest ALDX, IKT, VNDA, and AMRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/6/2026	Q2 2026	ALDX Aldeyra Therapeutics	-$0.0875	-$0.09	-$0.0025	-$0.09	$31.33 million	N/A
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	4.91	4.91
AMRN Amarin	N/A	3.67	2.67
IKT Inhibikase Therapeutics	N/A	15.82	15.82
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
AMRN Amarin	22.25%
IKT Inhibikase Therapeutics	3.81%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
AMRN Amarin	4.21%
IKT Inhibikase Therapeutics	7.10%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	6	60.33 million	53.21 million	Optionable
AMRN Amarin	80	21.12 million	20.23 million	Optionable
IKT Inhibikase Therapeutics	35	139.54 million	129.63 million	N/A
VNDA Vanda Pharmaceuticals	533	60.46 million	53.99 million	Optionable

ALDX, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

Oppenheimer initiates coverage of Vanda Pharmaceuticals with an outperform rating

September 23 at 12:46 PM | msn.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 7, 2026 | marketbeat.com

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

September 2, 2026 | prnewswire.com

BlackRock Inc. Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

September 1, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $1.32 Million in Vanda Pharmaceuticals Inc. $VNDA

August 31, 2026 | marketbeat.com

Ieq Capital LLC Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA

August 26, 2026 | marketbeat.com

Vanda Pharmaceuticals Inc. (VNDA)

August 25, 2026 | finance.yahoo.com

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

August 24, 2026 | prnewswire.com

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

August 22, 2026 | prnewswire.com

Vanda (VNDA) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

August 11, 2026 | zacks.com

Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Vanda Pharmaceuticals Balances Strong Growth With Rising Losses

August 5, 2026 | tipranks.com

Vanda: Q2 Earnings Snapshot

August 5, 2026 | chron.com

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2026 | zacks.com

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 5, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo Finance

July 29, 2026 | finance.yahoo.com

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

July 29, 2026 | prnewswire.com

Vanda Pharmaceuticals: Risks Rising, Rewards Dwindling - Why I'm Downgrading To Hold

July 17, 2026 | seekingalpha.com

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a ...

July 17, 2026 | uk.finance.yahoo.com

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

July 16, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, IKT, VNDA, and AMRN Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$1.30 -0.06 (-4.07%)

As of 11:30 AM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Amarin NASDAQ:AMRN

$13.46 -0.26 (-1.92%)

As of 11:26 AM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Inhibikase Therapeutics NASDAQ:IKT

$2.10 -0.06 (-2.56%)

As of 11:31 AM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.99 -0.06 (-1.09%)

As of 11:31 AM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALDX, IKT, VNDA, and AMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALDX, IKT, VNDA, and AMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALDX, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, IKT, VNDA, and AMRN Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Amarin NASDAQ:AMRN

Inhibikase Therapeutics NASDAQ:IKT

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALDX, IKT, VNDA, and AMRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALDX, IKT, VNDA, and AMRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALDX, IKT, VNDA, and AMRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, IKT, VNDA, and AMRN Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Amarin NASDAQ:AMRN

Inhibikase Therapeutics NASDAQ:IKT

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools